|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0000294,
umls-concept:C0005854,
umls-concept:C0030567,
umls-concept:C0038868,
umls-concept:C0205216,
umls-concept:C0242643,
umls-concept:C0393571,
umls-concept:C0449258,
umls-concept:C0542341,
umls-concept:C1537379,
umls-concept:C1704876,
umls-concept:C1838103
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2008-7-3
|
|
pubmed:abstractText |
Decreased blood-brain barrier (BBB) efflux function of the P-glycoprotein (P-gp) transport system could facilitate the accumulation of toxic compounds in the brain, increasing the risk of neurodegenerative pathology such as Parkinson's disease (PD). This study investigated in vivo BBB P-gp function in patients with parkinsonian neurodegenerative syndromes, using [11C]-verapamil PET in PD, PSP and MSA patients. Regional differences in distribution volume were studied using SPM with higher uptake interpreted as reduced P-gp function. Advanced PD patients and PSP patients had increased [11C]-verapamil uptake in frontal white matter regions compared to controls; while de novo PD patients showed lower uptake in midbrain and frontal regions. PSP and MSA patients had increased uptake in the basal ganglia. Decreased BBB P-gp function seems a late event in neurodegenerative disorders, and could enhance continuous neurodegeneration. Lower [11C]-verapamil uptake in midbrain and frontal regions of de novo PD patients could indicate a regional up-regulation of P-gp function.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-10613015,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-10701890,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-10706193,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-10923991,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-10975553,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-11091109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-11148226,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-11181832,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-11237734,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-11849198,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-12030260,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-12360103,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-12361330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-12427877,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-12635814,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-12724617,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-12834109,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-12865947,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-15109580,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-15381334,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-15488952,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-15535131,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-15542248,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-15576018,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-15668963,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-16092100,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-16401835,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-16523342,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-17255333,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-17287338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-2050758,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-2563168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-3419596,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-8710059,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-8917702,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-9769023,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18265929-9923759
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0300-9564
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1001-9
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18265929-Aged,
pubmed-meshheading:18265929-Blood-Brain Barrier,
pubmed-meshheading:18265929-Brain Mapping,
pubmed-meshheading:18265929-Carbon Isotopes,
pubmed-meshheading:18265929-Female,
pubmed-meshheading:18265929-Humans,
pubmed-meshheading:18265929-Male,
pubmed-meshheading:18265929-Middle Aged,
pubmed-meshheading:18265929-Multiple System Atrophy,
pubmed-meshheading:18265929-P-Glycoprotein,
pubmed-meshheading:18265929-Parkinson Disease,
pubmed-meshheading:18265929-Positron-Emission Tomography,
pubmed-meshheading:18265929-Supranuclear Palsy, Progressive,
pubmed-meshheading:18265929-Verapamil
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA.
|
|
pubmed:affiliation |
Department of Neurology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB Groningen, The Netherlands. a.l.bartels@neuro.umcg.nl
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
